GNI Group Ltd. is a global healthcare company that develops, manufactures, and sells pharmaceuticals and medical devices. The group operates two main business segments: the pharmaceutical business, which focuses on the research, development, and commercialization of compounds such as Aisuliu and F351, primarily in the Chinese market; and the medical device business, which is based in the United States and specializes in the development and sale of biomaterials and dental technologies. Key subsidiaries include Gyre Therapeutics, Inc., Cullgen Inc., and Berkeley Advanced Biomaterials LLC. The company maintains operational bases in Japan, China, the United States, and Australia, serving patients with unmet medical needs through its integrated drug discovery and manufacturing platform.

Summarised from the annual report, fiscal year ended Dec 2025

Industry Biotechnology Homepage gnipharma.com
Sector Healthcare IR page gnipharma.com/ir
Tags
pharmaceuticals, medical devices, biomaterials, drug discovery, dental technology, clinical development, Aisuliu, F351, Shanghai Genomics Co. Ltd., GNI Hong Kong Limited, Gyre Therapeutics Inc., Gyre Pharmaceuticals Co. Ltd., Cullgen Inc., Cullgen (Shanghai) Inc., Cullgen Australia Pty Ltd., Shanghai Leaf International Trading Co. Ltd., Berkeley Advanced Biomaterials LLC, Berkeley Biologics LLC, Myklen Healthcare Co. Ltd., ZOO LABO Co. Ltd.
Press page gnipharma.com/ir/news

Metrics

Valuation  
Market cap ¥ 198.278B
Market cap (USD) $ 1.239B
P/E -21.58
PEG —
P/BV 2.20
P/S 5.33
P/OCF -82.34
P/FCF -50.01
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.3%
ROI -7.7%
ROIC -4.7%
Profit margin -15.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 26.84B 23.612B 26.011B 17.419B 12.69B 9.774B 7.446B 5.019B 2.648B 1.307B 1.017B 474.717M 183.6M 161.943M
Net profit -4.244B 1.098B 8.094B 388.825M 1.066B 1.258B 181.841M -200.131M -175.206M -513.101M -675.058M -327.953M -730.776M -482.255M
Free cash flow -3.965B -4.701B 4.473B -1.547B 172.78M 1.064B 249.195M — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 3.405K 3.405K 2.831K 1.393K 1.481K 1.808K 2.624K — — — — — — —
Price performance 12m 0 0.2 1.03 -0.06 -0.18 -0.31 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (JPY) — — 821M 1.19B 1.37B 1.89B 3.12B 3.97B 6.24B 8.06B
↳ YoY growth +44.8% +15.1% +37.7% +65.6% +27.3% +56.9% +29.2%
↳ 5y CAGR +37.1% +39.3% +42.5%
Borrowings, current (JPY) — — 802M 691M 1.43B 700M 200M 1.3B 4.58B 1.33B
Borrowings, non-current (JPY) — — 1.52B 982M 1.26M — — 1.6B 1.2B 2.02B
Lease liabilities (JPY) — — — 366M 312M 426M 337M 399M 1.03B 1.33B
Cash and deposits (JPY) 2.6B 4.19B 4.87B 7.67B 10.3B 14.4B 11B 21.6B 10.1B 21.1B
Intangible assets (JPY) — — — — 1.72B 2.15B 2.93B 3.69B 11B 12.3B
Right-of-use assets (JPY) — — — 394M 732M 866M 755M 815M 1.56B 1.78B
Net debt (borrowings + leases - cash) (JPY) — — -2.55B -6B -8.58B -13.2B -10.5B -18.3B -3.31B -16.4B
Cash flow detail
Operating cash flow (JPY) -519M -315M 610M 789M 1.38B 552M 393M 6.55B -3.16B -2.41B
Purchases of property, plant and equipment (JPY) — — -774M -539M -260M -379M -974M -1.27B -523M -334M
Purchases of intangible assets (JPY) — — -71.1M -73.4M -53.3M -315M -966M -803M -1.01B -1.22B
Change in receivables (cash effect) (JPY) — — -121M -382M -186M -318M -1.09B 324M -1.87B -1.37B
Change in inventories (cash effect) (JPY) — — 20,000 -210M -136M -309M -205M 146M -90M -994M
Change in payables (cash effect) (JPY) — — 84.5M 59.7M 200M -92.2M 560M 6.28M -3.61M -911M
Dividends paid (cash effect) (JPY) — — — — — -151M — — — —
Share buybacks (cash effect) (JPY) — — -82,000 -64,000 — -172,000 -111,000 -38,000 -69,000 0.00
Interest paid (cash effect) (JPY) — — -39.3M -65.9M -48.1M -32.7M -27.8M -30.8M -104M -148M
Share-based compensation (JPY) — — — — — — 307M 1.16B 240M 2.21B
Operating cash flow before change in receivables (JPY) — — 742M 1.17B 1.56B 870M 1.49B 6.22B -1.3B -1.04B
Free cash flow (OCF - PPE - intangibles) (JPY) — — -224M 176M 1.06B -142M -1.55B 4.47B -4.7B -3.97B
Income detail
Research and development expense (JPY) — — 530M 758M 1.24B 2.02B 2.55B 2.56B 2.81B 3.3B
↳ 5y CAGR +37.0% +30.0% +21.5%
Total comprehensive income (JPY) -546M 119M 113M 398M 978M 1.58B 188M 10.7B 2.31B -6.33B
Comprehensive income to owners (JPY) -507M -124M -243M 41.8M 923M 2.38B 1.81B 8.92B 3.14B -3.79B
Segments
Medical Device · Segment revenue (JPY) — — 1.84B 1.82B 1.76B 1.92B 2.52B 3.06B 5.31B 7.68B
↳ YoY growth -1.1% -3.2% +8.8% +31.4% +21.3% +73.5% +44.7%
Medical Device · Segment operating income (JPY) — — 542M 865M 705M 642M 946M 1.08B 1.03B 533M
Pharmaceutical · Segment revenue (JPY) — — 3.21B 5.64B 8.05B 10.9B 15B 23B 18.3B 19.2B
↳ YoY growth +75.6% +42.5% +35.4% +37.6% +53.3% -20.3% +4.7%
Pharmaceutical · Segment operating income (JPY) — — 14.8M 422M 1.16B 983M 431M 12B 371M -4.01B
Reported Mar 29, 2017 Mar 30, 2018 Mar 31, 2020 Mar 31, 2021 Mar 28, 2022 Mar 28, 2022 Mar 28, 2024 Mar 28, 2024 Mar 31, 2025 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

2026年12月期 第3四半期決算説明資料 Bull 0 Bear 0 Routine

Prompts

GNI Group Ltd. (ticker 2160), listed in Japan.

ETFs Holding GNI Group Ltd.

ETF Weight in ETF Shares Market value As of
DFIS 0.02% 87,500 $ 1.107M Nov 12, 2026